Partner Carrie Hoffman was quoted in a Business Insurance article, “Gig economy firms get guidance on employee vs. contractor status,” about a U.S. Department of Labor opinion letter outlining when a worker should be considered an independent contractor or an employee.
Hoffman said employers should take into consideration the six factors outlined in the letter to determine whether an employee should be considered an independent contractor. “It isn’t a free ride,” she said. “You still have to follow the six factors.”
Employers also must carefully evaluate the laws of the states in which they operate to be sure they are not more restrictive than federal law, Hoffman said, which “makes the landscape tough for a nationwide employer.”
Hoffman said employers should take into consideration the six factors outlined in the letter to determine whether an employee should be considered an independent contractor. “It isn’t a free ride,” she said. “You still have to follow the six factors.”
Employers also must carefully evaluate the laws of the states in which they operate to be sure they are not more restrictive than federal law, Hoffman said, which “makes the landscape tough for a nationwide employer.”
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."